• Editas Medicine posted a Q2 2026 net loss of USD 18.2 million, narrowing from USD 53.2 million a year earlier.
• Revenue climbed to USD 11.9 million from USD 3.6 million, driven by deferred revenue recognized after certain BMS opt-in rights expired.
• R&D expense rose to USD 20.2 million from USD 16.2 million, while G&A expense fell to USD 11.6 million from USD 12.9 million.
• Cash and cash equivalents increased to USD 211.6 million at June 30 from USD 146.6 million at Dec. 31; cash runway guided into H2 2028.
• EDIT-401 remains on track for an Australia CTN submission this month; Phase 1/2 data update expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051601PRIMZONEFULLFEED9804311) on August 05, 2026, and is solely responsible for the information contained therein.